F-031
Fluconazole solution
2.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C13H12F2N6O
CAS Number:
Molecular Weight:
306.27
EC Number:
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24
Recommended Products
grade
certified reference material
form
liquid
feature
(Snap-N-Spike®)
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
concentration
2.0 mg/mL in methanol
technique(s)
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
application(s)
clinical testing
format
single component solution
storage temp.
−20°C
InChI
1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2
InChI key
RFHAOTPXVQNOHP-UHFFFAOYSA-N
Looking for similar products? Visit Product Comparison Guide
Related Categories
General description
Fluconazole, sold under trade names such as Trican, Monicure, Diflucan®, and Afungil, is an antifungal drug used in the treatment and prevention of superficial and systemic fungal infections. This Certified Spiking Solution® is suitable as starting material for calibrators, controls, or linearity standards for therapeutic drug monitoring or clinical and diagnostic testing of fluconazole in patient blood, serum, or plasma samples by HPLC or LC-MS/MS.
Application
- Gas chromatography-mass spectrometry determination of conjugated linoleic acids and cholesterol oxides and their stability in a model system.: This study employs the Equity-5 Capillary GC Column to determine conjugated linoleic acids and cholesterol oxides, demonstrating the column′s effectiveness in analyzing complex lipid matrices and its utility in ensuring precision and reliability in food chemistry and nutritional analysis (Yen et al., 2010).
- Comparison of series 5 gas chromatography column performances from a variety of manufacturers for separation of chlorinated dibenzo-p-dioxins and dibenzofurans using high-resolution mass spectrometry.: This research compares the performance of various series 5 GC columns, including the Equity-5 Capillary GC Column, for analyzing persistent organic pollutants. The study underscores the column′s efficiency in environmental analytics, particularly in the separation of complex mixtures of hazardous organic compounds (Fishman et al., 2004).
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Diflucan is a registered trademark of Pfizer, Inc.
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
related product
Product No.
Description
Pricing
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
Target Organs
Eyes,Central nervous system
Storage Class Code
3 - Flammable liquids
WGK
WGK 2
Flash Point(F)
49.5 °F - closed cup
Flash Point(C)
9.7 °C - closed cup
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Daniel K Benjamin et al.
JAMA, 311(17), 1742-1749 (2014-05-06)
Invasive candidiasis in premature infants causes death and neurodevelopmental impairment. Fluconazole prophylaxis reduces candidiasis, but its effect on mortality and the safety of fluconazole are unknown. To evaluate the efficacy and safety of fluconazole in preventing death or invasive candidiasis
Brent N Reed et al.
The Annals of pharmacotherapy, 44(1), 178-184 (2009-12-31)
To evaluate the literature regarding the use of fluconazole prophylaxis in high-risk neonates. Literature was accessed through MEDLINE (February 2001-August 2009) using the search terms fluconazole and prophylaxis, with limits for age group (ie, birth-18 y). Reference citations from identified
M A Pfaller et al.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 13(6), 180-195 (2010-11-06)
Both the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) have MIC clinical breakpoints (CBPs) for fluconazole (FLU) and Candida. EUCAST CBPs are species-specific, and apply only to C. albicans, C. tropicalis and
Rajendra J Kothavade et al.
Journal of medical microbiology, 59(Pt 8), 873-880 (2010-04-24)
Candida tropicalis has been identified as the most prevalent pathogenic yeast species of the Candida-non-albicans group. Historically, Candida albicans has been the major species responsible for causing candidiasis in immunocompromised and immunocompetent patients. However, infections (candidiasis) due to C. tropicalis
Mahipal Sinnollareddy et al.
Expert opinion on drug metabolism & toxicology, 7(11), 1431-1440 (2011-09-03)
Invasive candidiasis has emerged over the last few decades as an increasingly important nosocomial problem for the critically ill, affecting around 2% of intensive care unit patients. Although poor outcomes associated with invasive candidiasis among critically ill patients may relate
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service